Peters Ulrike, Askling Johan, Gridley Gloria, Ekbom Anders, Linet Martha
Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892-7273, USA.
Arch Intern Med. 2003 Jul 14;163(13):1566-72. doi: 10.1001/archinte.163.13.1566.
Patients with celiac disease have an increased risk of death from gastrointestinal malignancies and lymphomas, but little is known about mortality from other causes and few studies have assessed long-term outcomes.
Nationwide data on 10 032 Swedish patients hospitalized from January 1, 1964, through December 31, 1993, with celiac disease and surviving at least 12 months were linked with the national mortality register. Mortality risks were computed as standardized mortality ratios (SMRs), comparing mortality rates of patients with celiac disease with rates in the general Swedish population.
A total of 828 patients with celiac disease died during the follow-up period (1965-1994). For all causes of death combined, mortality risks were significantly elevated: 2.0-fold (95% confidence interval [CI], 1.8-2.1) among all patients with celiac disease and 1.4-fold (95% CI, 1.2-1.6) among patients with celiac disease with no other discharge diagnoses at initial hospitalization. The overall SMR did not differ by sex or calendar year of initial hospitalization, whereas mortality risk in patients hospitalized with celiac disease before the age of 2 years was significantly lower by 60% (95% CI, 0.2-0.8) compared with the same age group of the general population. Mortality risks were elevated for a wide array of diseases, including non-Hodgkin lymphoma (SMR, 11.4), cancer of the small intestine (SMR, 17.3), autoimmune diseases (including rheumatoid arthritis [SMR, 7.3] and diffuse diseases of connective tissue [SMR, 17.0]), allergic disorders (such as asthma [SMR, 2.8]), inflammatory bowel diseases (including ulcerative colitis and Crohn disease [SMR, 70.9]), diabetes mellitus (SMR, 3.0), disorders of immune deficiency (SMR, 20.9), tuberculosis (SMR, 5.9), pneumonia (SMR, 2.9), and nephritis (SMR, 5.4).
The elevated mortality risk for all causes of death combined reflected, for the most part, disorders characterized by immune dysfunction.
乳糜泻患者死于胃肠道恶性肿瘤和淋巴瘤的风险增加,但对于其他原因导致的死亡率知之甚少,且很少有研究评估长期预后。
1964年1月1日至1993年12月31日期间在瑞典住院且存活至少12个月的10032例乳糜泻患者的全国性数据与国家死亡率登记册相关联。死亡率风险以标准化死亡率(SMR)计算,将乳糜泻患者的死亡率与瑞典普通人群的死亡率进行比较。
在随访期间(1965 - 1994年),共有828例乳糜泻患者死亡。对于所有死因合并计算,死亡率风险显著升高:所有乳糜泻患者中为2.0倍(95%置信区间[CI],1.8 - 2.1),初次住院时无其他出院诊断的乳糜泻患者中为1.4倍(95%CI,1.2 - 1.6)。总体SMR在性别或初次住院的日历年方面没有差异,而2岁前因乳糜泻住院的患者与普通人群同年龄组相比,死亡率风险显著降低60%(95%CI,0.2 - 0.8)。多种疾病的死亡率风险升高,包括非霍奇金淋巴瘤(SMR,11.4)、小肠癌(SMR,17.3)、自身免疫性疾病(包括类风湿关节炎[SMR,7.3]和结缔组织弥漫性疾病[SMR,17.0])、过敏性疾病(如哮喘[SMR,2.8])、炎症性肠病(包括溃疡性结肠炎和克罗恩病[SMR,70.9])、糖尿病(SMR,3.0)、免疫缺陷疾病(SMR,20.9)、结核病(SMR,5.9)、肺炎(SMR,2.9)和肾炎(SMR,5.4)。
所有死因合并的死亡率风险升高在很大程度上反映了以免疫功能障碍为特征的疾病。